Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Spina

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The International Journal of Biological Markers|November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trialStefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trialCristin Roma, Riziero Esposito Abate, Alessandra Sacco, et al.
Cell Death Discovery|March 28, 2026
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cellsFederica Auletta, Caterina Ieranò, Dario Guido Di Febbraro, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Cancer Research Communications|December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patientsDaniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
The Lancet. Oncology|April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trialSandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
Cancers|October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational StudyDaniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The International Journal of Biological Markers|November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trialStefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2024
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trialCristin Roma, Riziero Esposito Abate, Alessandra Sacco, et al.
Cell Death Discovery|March 28, 2026
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cellsFederica Auletta, Caterina Ieranò, Dario Guido Di Febbraro, et al.
NPJ Precision Oncology|November 17, 2025
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trialEliana Pivetta, Vincenzo Canzonieri, Marina Bagnoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 11, 2023
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trialLuca Forlani, Loris De Cecco, Vittorio Simeon, et al.
Cancers|April 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer PatientsCrescenzo D'Alterio, Anna Spina, Laura Arenare, et al.
Cancer Research Communications|December 19, 2025
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patientsDaniela Criscuolo, Francesco Merolla, Benedetta Pellegrino, et al.
British Journal of Cancer|July 22, 2022
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)Lucia Musacchio, Daniela Califano, Michele Bartoletti, et al.
The Lancet. Oncology|April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trialSandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
Cancers|October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational StudyDaniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
Pageof 3